

Amlodipine (Norvasc®)

Selected References:

- Ahn HK, et al. 2007. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. *Hypertension in pregnancy*, 26(2):179-187.
- Aoki H, et al. 2018. Low Levels of Amlodipine in Breast Milk and Plasma. *Breastfeeding medicine*, 13(9):622-626.
- Centers for Disease Control and Prevention. (2024). Health and economic benefits of high blood pressure interventions. Retrieved August 2024 from <https://www.cdc.gov/nccdphp/priorities/high-blood-pressure.html>.
- Faham DE, et al. 2019. Can Amlodipine Improve the Pre-ovulatory Follicle Blood Flow in Women with Polycystic Ovarian Syndrome?. *Journal of reproduction & infertility*, 20(2):89-94.
- Ishikawa T, et al. 2023. Risk of major congenital malformations associated with first-trimester antihypertensives, including amlodipine and methyldopa: A large claims database study 2010-2019. *Pregnancy hypertension*, 31:73-83.
- Magee LA, et al. 1996. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. *Am J Obstet Gynecol*, 174(3):823-828.
- Mito AA, et al. 2019. Safety of Amlodipine in Early Pregnancy. *Journal of the American Heart Association*, 8(15):1-7.
- Morgan JL, et al. 2018. Pharmacokinetics of amlodipine besylate at delivery and during lactation. *Pregnancy hypertension*, 11:77-80.
- Naito T, et al. 2015. Amlodipine passage into breast milk in lactating women with pregnancy-induced hypertension and its estimation of infant risk for breastfeeding. *Journal of human lactation*, 31(2):301-306.
- Rosbotham JL, et al. 1998. Painful subcutaneous fat necrosis of the newborn associated with intra-partum use of a calcium channel blocker. *Clinical and experimental dermatology*. 23(1):19-21.
- Szucs KA, et al. 2010. Maternal membranous glomerulonephritis and successful exclusive breastfeeding. *Breastfeeding Medicine*, 5(3):123-126.
- S. Food and Drug Administration. (2011). Norvasc (Amlodipine besylate) tablets label. Retrieved August 2024 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s047lbl.pdf.
- Vigil-De Gracia P, et al. 2014. Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial. *The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians*, 27(13): 1291-1294.
- Yin J, et al. 2022. Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis. *Archives of Gynecology and Obstetrics*, 306(6):1891-1900.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 1, 2024.

Amlodipine (Norvasc®)

Selected References:

- Auffret M, et al. 2016. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication? *Eur J Obstet Gynecol Reprod Biol*, 207:188-192.
- Baev OR, et al. 2017. Outcomes of mifepristone usage for cervical ripening and induction of labour in full-term pregnancy. Randomized controlled trial. *Eur J Obstet Gynecol Reprod Biol*, 217:144-149.
- Brown A, et al. 2002. Daily low dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomised controlled trial of 2 and 5 mg per day for 120 days. *J Clin Endocrinol Metab*, 87:63-70.
- Bos-Thompson MA, et al. 2008. Mobius syndrome in a neonate after mifepristone and misoprostol elective abortion failure. *Ann Pharmacother*, 42(6):888-892.
- Chen A, et al. 2004. Mifepristone-induced early abortion and outcome of subsequent wanted pregnancy. *Am J Epidemiol*, 160(2):110-117.
- Gary MM, Harrison DJ. 2006. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. *Ann Pharmacother*, 40:191-197.
- Glasier A, et al. 1992. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. *N Engl J Med*, 327:1041-1044.
- Juneja SC, Dodson MG. 1990. In vitro effect of RU 486 on sperm-egg interaction in mice. *Am J Obstet Gynecol*, 163:216-221.
- Lakha F, et al. 2007. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). *Hum Reprod*, 22(9):2428-2436.
- Liao H, et al. 2011. Repeated medical abortions and the risk of preterm birth in the subsequent pregnancy. *Arch Gynecol Obstet*, 284(3):579-586.
- Lim BH, et al. 1990. Normal development after exposure to mifepristone in early pregnancy. *Lancet*, 336:257-258.
- Mifepristone Drug Label. 2023. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b63fad9b-7f12-4400-9019-b0586054e534>.
- Peyron R, et al. 1993. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. *N Engl J Med*, 328:1509-1513.
- Pons JC, et al. 1991. Development after exposure to mifepristone in early pregnancy. *Lancet*; 338:763.
- Saav I, et al. 2010. Medical abortion in lactating women-low levels of mifepristone in breast milk. *Acta Obstet Gynecol Scand*, 89(5):618-622.
- Sanchez-Criado JE, et al. 1990. A possible dual mechanism of the anovulatory action of antiprogesterone RU486 in the rat. *Biol Reprod*, 42:877-886.
- Shoupe D, et al. 1987. Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late

follicular phase. Am J Obstet Gynecol, 157:1421-1426.

- Sitruk-Ware R, Davey A, Sakiz E. 1998. Fetal malformations and failed medical termination of pregnancy. Lancet, 352:323.
- Swahn ML, et al. 1996. Contraception with anti-progesterone. Baillieres Clin Obstet Gynaecol, 10(1):43-53.
- Task force on postovulatory methods of fertility regulation. 1999. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet 353:607-702.
- van der Schoot P, et al. 1987. Effects of the progesterone antagonist RU486 on ovarian activity in the rat. Endocrinology, 121:1375-1382.
- Wolf JP, et al. 1990. Tolerance of perinidatory primate embryos to RU 486 exposure in vitro and in vivo. Contraception, 41:85-92.
- Yang YQ, Wu JT. 1990. RU 486 interferes with egg transport and retards the in vivo and in vitro development of mouse embryos. Contraception, 41:551-556.
- Zhu QX, et al. 2009. Mifepristone-induced abortion and placental complications in subsequent pregnancy. Hum Reprod, 24(2):315-319.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 1, 2024.

Amlodipine (Norvasc®)

Selected References:

- American College of Obstetricians and Gynecologists (ACOG). 2022/Apr. Preeclampsia and High Blood Pressure during Pregnancy.
<https://www.acog.org/womens-health/faqs/preeclampsia-and-high-blood-pressure-during-pregnancy>
- Anderson PO, et al 2020. Drug treatment of Raynaud's phenomenon of the nipple. Breastfeed Med 15:686-8.
- Benoff S, et al. 1994. The effect of calcium ion channel blockers on sperm fertilization potential. Fertil Steril 62:606-17.
- Bortolus R, et al. 2000. Nifedipine administered in pregnancy: Effect on the development of children at 18

months. BJOG 107:792-794.

- Davis RL, et al 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. *Pharmacoepidemiol Drug Saf* 20:13-145.
- Dublin S, et al. 2022. Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: a retrospective cohort study. *PLoS One* 17(5):e0268284
- George R, et. 2022. Comparative efficacy and safety of oral nifedipine with other antihypertensive medications in the management of hypertensive disorders of pregnancy: a systematic review and meta-analysis of randomized controlled trials. *J Hypertens* 40(10):1876-1886.
- Houtzager BA, et al. 2006. Long-term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. *BJOG*. 2006 Mar; 113(3):324-31.
- Magee LA, et al. 1996. The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study. *Am J Obstet Gynecol* 174:823-828.
- Malfar BN, et al. 2019. ABCG2 c.421C>A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women. *Reprod Toxicol* 85:1-5.
- Penny WJ, Lewis MJ. 1989. Nifedipine is excreted in human milk. *Eur J Clin Pharmacol*. 36(4):427-8.
- Tabacova SA, et al. 2002. Developmental abnormalities reported to FDA in association with nifedipine treatment in pregnancy. *Teratology*; 65:368.
- Taddio A, et al 1996. Is nifedipine use during labor and breast-feeding safe for the neonate? *Clin Investig Med* 19:S11. Abstract.
- Weber-Schoendorfer C, et al. 2008. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. *Reprod Toxicol* 26(1): 24-30.
- Wu M, et al 2012. Raynaud’s phenomenon of the nipple. *Obstet Gynecol*. 119(2 Pt 2):447-9.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 1, 2024.

Amlodipine (Norvasc®)

- Agrawal M, et al. 2022. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis. *Clinical endocrinology*, 96(6):857-868.
- Akmal A, Kung J. 2014. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity. *Expert Opin Drug Saf*, 13(10):1397-1406.
- Alexander EK, et al. 2017. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. *Thyroid: official journal of the American Thyroid Association*, 27(3):315-389.
- American College of Obstetricians and Gynecology. 2020. Thyroid disease in pregnancy. *ACOG Practice Bulletin*, Number 223. *Obstet Gynecol*, 135(6):e261-e274.
- Andersen SL, et al. 2013. Birth Defects after early pregnancy use of antithyroid drugs: A Danish nationwide study. *J Clin Endocrinol Metab*, 98(11):4374-4381.
- Andersen SL, et al. 2017. Birth Defects after early pregnancy use of antithyroid drugs: A Swedish nationwide study. *Euro J Endocrinol*, 177(4):369-378.
- Andersen SL, Andersen S. 2020. Antithyroid drugs and birth defects. *Thyroid Res*, 13:11.
- Arata N, et al. 2012. Pregnancy outcomes of exposure to methimazole (POEM) study: an interim report. *Japanese journal of clinical medicine*, 70(11):1976-1982.
- Awosika AO, et al. 2023. Methimazole. *StatPearls* [Internet], Treasure Island (FL), available from: <https://www.ncbi.nlm.nih.gov/books/NBK545223/>
- Azizi F. 2003. Thyroid function in breast-fed infants is not affected by methimazole-induced maternal hypothyroidism: results of a retrospective study. *J Endocrinol Invest*, 26:301-304.
- Baid SK, Merke DP. 2007. Aplasia cutis congenita following in utero methimazole exposure. *J Pediatr Endocrinol Metab*, 20:585-586.
- Barbero P, et al. 2008. Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study. *Am J Med Genet*, 146A(18):2390-2395.
- Cassina M, et al. 2012. Pharmacologic treatment of hyperthyroidism during pregnancy. *Birth Defects Res A Clin Mol Teratol*, 94(8):612-619.
- Chan GW, Mandel SJ. 2007. Therapy insight: management of Graves' disease during pregnancy. *Nat Clin Pract Endocrinol Metab*; 3(6):470-8.
- Chen CH, et al. 2011. Risk of adverse perinatal outcomes with antithyroid treatment during pregnancy: a nationwide population-based study. *BJOG*, 118:1365-1373.
- Clementi M, et al. 1999. Methimazole embryopathy: delineation of the phenotype. *Am J Med Genet*, 83:43-46.
- Committee on Drugs, American Academy of Pediatrics. 2001. The transfer of drugs and other chemicals into human breast milk. *Pediatrics*, 108:776-789.
- Cooper DS. 1987. Antithyroid drugs: to breast-feed or not to breast-feed. *Am J Obstet Gynecol*, 157:234-235.
- Diav-Citrin O, Ornoy A. 2002. Teratogen update: antithyroid drugs-methimazole, carbimazole, and propylthiouracil. *Teratology*, 65:38-44.
- Di Gianantonio E, et al. 2001. Adverse effects of prenatal methimazole exposure. *Teratology*, 64(5):262-266.
- Dumitrescu MC, et al. 2002. Choanal stenosis, hypothelia, deafness, recurrent dacryocystitis, neck fistulas, short stature, and microcephaly: report of a case. *Am J Med Genet*, 113:295-297.
- Dumitrascu MC, et al. 2021. Hyperthyroidism management during pregnancy and lactation (Review). *Exp Ther Med*, 22(3):960.
- Eisenstein Z, et al. 1992. Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero. *Eur J Pediatr*, 151:558-559.
- Ferraris S, et al. 2003. Malformations following methimazole exposure in utero: an open issue. *Birth Defects Res*

(Part A), 67:989-992.

- Francis T, et al. 2020. Safety of antithyroid drugs in pregnancy: update and therapy implications. *Expert Opin Drug Saf*, 19(5):565-576.
- Gianetti E, et al. 2015. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. *J Endocrinol Invest*, 38(9):977-985.
- Greenberg F. 1987. Brief clinical report: Choanal atresia and athelia: Methimazole teratogenicity or a new syndrome? *Am J Med Genet*, 28:931-934.
- Gripp KW, et al. 2011. Grade 1 microtia, wide anterior fontanel and novel type trachea-esophageal fistula in methimazole embryopathy. *Am J Med Genet A*, 155A(3):526-533.
- Howley MM, et al. 2017. Thyroid medication use and birth defects in the National Birth Defects Prevention Study. *Birth Defects Res*, 109(18):1471-1481.
- Hudzik B, Zubelewicz-Szkodzinska B. 2016. Antithyroid drugs during breastfeeding. *Clin Endocrinol (Oxf)*, 85(6):827-830.
- Johnsson E, et al. 1997. Severe malformations in infant born to hyperthyroid woman on methimazole. *Lancet*, 350:1520.
- Karlsson FA, et al. 2002. Severe embryopathy and exposure to methimazole in early pregnancy. *J Clin Endocrinol Metab*, 87(2):947-949.
- Korelitz JJ, et al. 2013. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. *Thyroid*, 23:758-765.
- Martin-Denavit T, et al. 2000. Ectodermal abnormalities associated with methimazole intrauterine exposure [letter]. *Am J Med Genet*, 94:338-340.
- Methimazole tablets, USP Prescribing Information. Par Pharmaceutical Companies, Inc. Spring Valley, NY 10977. Accessed May 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/040350s016lbl.pdf
- Mitsuda N, et al. 1992. Risk factors for developmental disorders in infants born to women with Graves disease. *Obstet Gynecol*; 80(3 Pt 1):359-64.
- Momotani M, et al. 1984. Maternal hyperthyroidism and congenital malformation in the offspring. *Clin Endocrinol (Oxford)*, 20:695-700.
- Purnamasari D, et al. 2019. Gastroschisis Following Treatment with High-Dose Methimazole in Pregnancy: A Case Report. *Drug Saf Case Rep*, 6(1):5.
- Radetti G, et al. 2002. Foetal and neonatal thyroid disorders. *Minerva Pediatr*; 54(5):383-400.
- Rasmussen SA, et al. 2007. Maternal thyroid disease as a risk factor for craniosynostosis. *Obstetrics and gynecology*, 110(2 Pt 1):369-377.
- Romeo AF, Obican SG. 2020. Teratogen Update: Antithyroid Medications. *Birth Defects Res*, 112(15):1150-1170.
- Sargent KA, et al. 1994. Apparent scalp-ear-nipple (Findlay) syndrome in a neonate exposed to methimazole in-utero. *Am J Hum Genet*, 55:A312.
- Sato Y, et al. 2014. A case of fetal hyperthyroidism treated with maternal administration of methimazole. *J Perinatol*, 34(12):945-347.
- Seo GH, et al. 2018. Antithyroid drugs and congenital malformations. A nationwide Korean cohort study. *Ann Intern Med*, 168(6):405-413.
- Seoud M, et al. 2003. Gastrointestinal malformations in two infants born to women with hyperthyroidism untreated in the first trimester. *Am J Perinatol*, 20:59-62.
- Shepard TH, et al. 2002. Update on new developments in the study of human teratogens. *Teratology*, 65(4):153-161.
- Stagnaro-Green A, et al. 2011. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. *Thyroid*, 21:1081-1125.
- Tegler L, Lindstrom B. 1980. Antithyroid drugs in milk. *Lancet*, 2:591.
- The WHO Working Group, Bennet PN (ed). 1988. *Drugs and Human Lactation*. Elsevier, Amsterdam, New York, Oxford, pp. 196-197.

- Tonacchera M, et al. 2020. Treatment of Graves' hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy. *J Endocrinol Invest*, 43(2):257-265.
- Wilson LC, et al. 1998. Choanal atresia and hypothelia following methimazole exposure in utero: a second report. *Am J Med Genet*, 75:220-222.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 1, 2024.

Amlodipine (Norvasc®)

Selected References:

- Camera G and Pregliasco P. 1992. Ear malformation in baby born to mother using isotretinoin cream. *Lancet*, 339:687.
- De Wals P. et al. 1991. Association between holoprosencephaly and exposure to topical retinoids: results of the EUROCAT survey. *Paediatr Perinat Epidemiol*, 5:445-447.
- Jick S, et al. 1993. First trimester topical tretinoin and congenital disorders. *Lancet*, 341:1181-1182.
- Kaplan YC, et al. 2015. Pregnancy outcomes following first-trimester exposure to topical retinoids: A systematic review and meta-analysis. *Br J Dermatol*, 173:1132-1141.
- Loureiro KD, et al. 2005. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. *American Journal of Medical Genetics*, 136A:117-121.
- Lipson AH, et al. 1993. Multiple congenital defects associated with maternal use of topical tretinoin. *Lancet*, 341:1352-1353.
- MacDonald SC, et al. 2019. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance. *Pharmacoepidemiol Drug Saf* 28(9):1211-1221.
- Panchaud A, et al. 2012. Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study. *J Clin Pharmacol*, 52:1844-1851.
- Ross SA, et al. 2000. Retinoids in embryonal development. *Physiol Rev*, 80(3):1021-1054.

- Selcen D, et al. 2000. Otocerebral anomalies associated with topical tretinoin use. Brain Dev 22:218-220.
- Shapiro L, et al. 1997. Safety of first trimester exposure to topical tretinoin: prospective cohort study. Lancet, 350:1143-1144.
- Veraldi S, et al. 2016. Are topical retinoids teratogenic? G Ital Dermatol Venereol. 151(6):700-705.
- Williams AL et al. 2020. Teratogen update: Topical use and third-generation retinoids. Birth Defects Res, 112(15):1105-1114.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 1, 2024.